New research explores the potential of digital cognitive assessments to detect subtle, domain-specific changes associated with early Alzheimer’s disease pathology. To view this data and other Cogstate posters presented at AAIC 2026, visit buff.ly/DqhqkZc

Psychedelic trials present unique challenges for endpoint quality. Central Rating helps sponsors support blinding, reduce variability, and strengthen confidence: in clinician-rated outcomes such as MADRS. buff.ly/xKHLk9o

For MADRS and HAM-D assessments, seemingly small differences in their administration can affect endpoint data quality. We revisit 3 common rater errors and practical considerations for strengthening rater training and calibration. Read the blog: buff.ly/AD8c1Wa

Join Join Luka Lucić, PhD, and Svenja Wacker, PhD, for an upcoming webinar exploring a signal intelligence framework for distinguishing meaningful clinical improvement from measurement noise and other sources of pseudo-improvement. Register now: buff.ly/isCLP18

We’re honored to announce that Cogstate has been selected to support cognitive measurement in the XPRIZE Healthspan competition, a 7-year, $101 million global competition designed to revolutionize human aging. Read the announcement: buff.ly/mI1ewnr

Our latest blog explores why an end-to-end strategy is becoming increasingly important for rare disease research and how integrated approaches to rater training, eCOA design, and central monitoring can help improve confidence in trial outcomes. Read more: buff.ly/HRib6Vg

Can lifestyle interventions meaningfully slow cognitive decline? Results from the US POINTER trial suggest they can. Cogstate is proud to support research in this area through validated cognitive assessments. Read the study: buff.ly/SXNfNvB

The countdown to #AAIC26 is on! In just a few weeks, the Cogstate team will join the global Alzheimer's disease research community in London. Explore Cogstate's full list of AAIC 2026 presentations: buff.ly/nmE3pYy

It's National Work from Home Day—but at Cogstate, that’s every day. As a virtual‑first organization, flexibility is just one part of how we enable our teams to do their best work. Interested in joining us? Explore opportunities on our careers page: buff.ly/SbCIHSb

Our US offices are closed today in observance of Juneteenth, a day that marks a time when freedom was delayed, and a reminder that inequity doesn't end with declaration. It’s a time to reflect on progress and consider how each of us contributes to a more equitable future.

London, here we come! We're thrilled to join the global Alzheimer's disease community at #AAIC26 and discuss what's next for AD research. Schedule a meeting 👉 buff.ly/nmE3pYy

Recent research on NGLY1 Deficiency Disorder highlights how longitudinal cognitive and functional data can inform endpoint selection, expected trajectories, and meaningful change (Morrison et al., Human Molecular Genetics). Read the publication: buff.ly/E33hsgj

A new study by Prof. Paul Maruff and co-authors shows that remote, unsupervised cognitive testing using the Cogstate Brief Battery delivers results comparable to in-clinic assessments—and remains sensitive to early cognitive decline. Read the publication: buff.ly/WurHaS6

Recent work from Rachel Buckley and team examining p‑Tau217, tau aggregation, and cognitive decline in preclinical AD suggests that disease trajectories—and their cognitive expression—can differ by sex. Read the publication: buff.ly/ZGPF8ID

With strong sensitivity, specificity, and predictive value, the FCSRT can be a useful endpoint in preclinical and early AD trials. Read quick insights from Cogstate experts on how to ensure the FCSRT yields high quality data for accurate decision making: buff.ly/9CmvjvN

Are you developing a sleep disorder medicine? Join Prof. Paul Maruff for an upcoming webinar where he’ll review a data-driven framework for understanding the nature and magnitude of cognitive impairment in sleep disorder drug development. Register now: buff.ly/lFF2cb2

Placebo response rates in major depressive disorder (MDD) trials can reach as high as 30-40%, obscuring true treatment effects. Join us for a webinar on mitigating placebo response and enhancing signal detection in MDD clinical trials. Register here: buff.ly/sliN5KU

This JAMA Neurology article co-authored by Prof Paul Maruff features a recent P2 trial for adults with NT1, where treatment with the oral OX2R-selective agonist oveporexton resulted in significant improvements in attention, executive function, and memory. buff.ly/3c6SxTf

Svenja Wacker, PhD (Neuropsychology Science Director) presented data at the 2025 ISCTM Spring Conference showcasing the strengths of the Cogstate Brief Battery as a valid option for remote, self-administered cognitive testing via smartphone. Learn more: buff.ly/juxSbOg

The CDR scale's ability to detect meaningful change depends on rater expertise, rigorous training, and careful protocol planning. Our latest blog explores practical strategies to increase signal detection and ensure reliable outcomes in your AD studies. buff.ly/EA3sO8u